Given that mutant COL1A1 is known to cause Osteogenesis Imperfecta (OI), tools to modulate COL1A1 expression are likely to be of significant therapeutic value. In this context, we have evaluated RNA interference (RNAi) as a means to downregulate COL1A1 expression in Cos-7 cells and in human mesenchymal progenitor stem cells (MPCs), the latter cells giving rise to bone and therefore representing a target cell type for collagen-related disorders. In addition, allele-specificity, a key factor to the success of RNAi-based suppression, was explored with a view to developing a mutation-independent RNAi-based therapeutic for OI by targeting an intragenic SNP within transcripts derived from the COL1A1 gene. Preferential suppression of individual polymorphic alleles that differed by a single nucleotide was observed.
Introduction
Over 150 COL1A1 mutations give rise to the brittle bone disease Osteogenesis Imperfecta (OI) (http://www. le.ac.uk/ genetics/collagen/). It would therefore be preferable to suppress mutant COL1A1 alleles in a mutation-independent manner. 1 -4 Clearly, efficiency and specificity are key factors in the efficacy of a suppression-based therapeutic and RNA interference (RNAi) represents a powerful new tool. 5 However, some studies show that RNAi may not be sequence specific at the level of a single nucleotide. 5 It is therefore imperative, when contemplating using RNAibased therapies, to determine whether allele-specificity really can be achieved. Mesenchymal progenitor stem cells (MPCs) are stem cells, which can give rise to bone and which represent target cells for OI therapies. Engraftment of donor MPCs has been achieved in children with OI. 6 However, the use Results siRNA studies for OI therapeutics Three mutation-independent siRNAs targeting a polymorphic region in the COL1A1 gene were evaluated in human MPCs. siRNAT1 and siRNAT2 were designed to target the T-allele variant whereas siRNAC targets the C-allele variant of COL1A1. 7,1,2,4 MPCs were homozygous (MPC-T/T) or heterozygous (MPC-C/T) for the polymorphism.
All siRNAs suppressed COL1A1 (Table 1) . siRNAT2 downregulates the T-allele of COL1A1 in MPC-T/T cells more than either siRNAT1 or siRNAC (84.62, 65.23, 67.66 respectively) (P ¼ 0.004 and 0.01). siRNAT1 and siRNAC are equally active in these cells even though siRNAC has a single-base mismatch with respect to its target (P ¼ 0.7). When both siRNAT1 and siRNAC or siRNAT2 and siRNAC are transfected together, lower levels of suppression are achieved than with either siRNAT2 or siRNAC alone, suggesting that the two siRNAs may compete/interfere with one another.
In MPC-C/T cells, siRNAT2 and siRNAC are better than siRNAT1 at suppressing COL1A1 (Po0.0001). Unlike the results found in MPC-T/T cells, siRNAC is better than siRNAT2 at downregulating the combined C-and T-allele transcripts found in the MPC-C/T cells (Po0.0001). This suggests that siRNAC may be better at downregulating the C-allele of COL1A1 than siRNAT2 is at downregulating the T-allele. This is corroborated by the fact that lower levels of suppression are achieved with both siRNAT2 and siRNAC than with siRNAC singly (Po0.0001). When siRNAT1 and siRNAC or siRNAT2 and siRNAC were evaluated in MPCs together, an intermediate level of suppression to that obtained with each siRNA singly was found.
Results quantifying de novo formed Type I collagen protein, excreted from MPC-T/T cells transfected with siRNAs, provide evidence that suppression of RNA is mirrored at the protein level (Table 2) . Again, siRNAT2 was the most efficient siRNA, followed by siRNAC and siRNAT1. Protein levels were suppressed by up to 72%.
Since MPC cells with the rare homozygous C-allele genotype were not available, siRNAs were evaluated in Cos-7 cells expressing a partial C-or T-allele COL1A1 gene. Downregulation of up to 65% was observed. As found in MPCs, siRNAT2 was more active than siRNAT1. In addition, all three siRNAs targeted their own correct target allele better than their incorrect allele, showing allele preference rather than allele-specificity (Table 1) .
Discussion
The use of mutation-independent siRNAs targeting a common and therefore potentially therapeutically significant polymorphism in the COL1A1 gene has been investigated. While levels of COL1A1 suppression of up to 85% were observed, none of the siRNAs evaluated were found to be completely allele-specific. Specificity of siRNA at the single-nucleotide resolution has been achieved in a number of studies. 5,10 -12 One suggests that to achieve sequence-specificity, small amounts of siRNA should be used. 5 Another study does not confirm this. 5 The positioning of a single-nucleotide mismatch within the siRNA molecule at position 9, 10 or 11 of the target (from the 5 0 end of the target and not including 3 0 siRNA overhang sequences) may convey specificity. 5, 10, 11 In our study the single mismatch was situated at position 3 (siRNAT2 and siRNAC) or 11 (siRNAT1). Constraints due to COL1A1 target sequence disallowed the study of additional siRNAs targeting this polymorphism. In summary, RNAi-based suppression of COL1A1 has been demonstrated in MPCs and allele-specificity evaluated. Clearly, in many cases, the lack of allele-specificity will be an enormous barrier when using RNAi to suppress mutant alleles. In addition, constraints incurred by both the target sequence and the necessity to design molecules that will not target multiple genes will be challenging when designing RNAi therapeutics. The use of mutationindependent RNAi targets, such as polymorphic sites, is therefore appealing. 
